UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. HIV感染症の治療に用いる抗レトロウイルス薬の概要overview of antiretroviral agents used to treat hiv [show details]
… mg dose given with a pharmacokinetic booster has not been established. Tenofovir can lead to kidney injury and bone loss; however TAF is associated with less renal and bone toxicity compared with TDF since …
2. 成人のB型肝炎ワクチン接種hepatitis b virus immunization in adults [show details]
… years received a booster dose of the vaccine; a titer of ≥10 milli-international units/mL was seen in approximately 93 percent six weeks after receiving the booster dose.… individuals, smokers, and men, and significantly lower in patients with diabetes, cirrhosis, chronic renal failure, organ transplant recipients, children with celiac disease, and immunosuppressed patients …
3. ウイルス量の増殖を抑制できているHIV-1成人患者への抗レトロウイルス薬の切り替えswitching antiretroviral therapy for adults with hiv 1 and a suppressed viral load [show details]
… combination of TDF plus a boosted PI carries a higher risk of TDF-induced renal toxicity than other combinations; so, for patients with risk factors for renal disease, we often change the boosted PI and TDF if the …
4. 実質臓器移植の候補者およびレシピエントにおける予防接種immunizations in solid organ transplant candidates and recipients [show details]
… levels of antibody , and booster doses produce suboptimal responses . These results underscore the value of pretransplant immunization, ideally done prior to the onset of advanced renal or liver failure. …
5. 薬物療法の最新情報whats new in drug therapy [show details]
…indicates that a second booster dose with an mRNA vaccine is an option for any individual who received Ad26.COV2.S (Janssen/Johnson and Johnson) for both the primary and booster doses. Vaccine effectiveness …